Genmab has agreed to a deal that could be worth over $1.1 billion with a unit of Johnson & Johnson for the rights to a cancer agent, giving the U.S. company a 10.7% equity stake in the Danish biotech group.
Genmab, Johnson & Johnson agree to $1.1 billion deal
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.